ARTICLE | Company News
Emergent BioSolutions, U.S. Centers for Disease Control and Prevention infectious news
August 18, 2014 7:00 AM UTC
Emergent said the CDC exercised options under a 2012 award valued at $18.9 million over three years for Emergent to supply Vaccinia Immune Globulin Intravenous (VIGIV) for the U.S. strategic national...